Recent Articles
Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?
MAPS co-executive director Ismail Lourido Ali on what the April 2026 executive order, the Texas and Colorado funding fights, and Gabon’s new iboga decree mean for who gets access to ibogaine and who benefits from it.
By Ismail L. Ali, JD
The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science
By Josh Lipson, PhD and Roman Palitsky, MDiv, PhD
Filter
Psilocybin Trial in Veterans With Treatment-Resistant PTSD Reports 75% Remission at One Month
Nine of twelve veterans with severe, treatment-resistant PTSD no longer met diagnostic criteria a month…
By Joe Moore
Psychedelic Policy Briefing: Week of July 27th, 2026
The House voted to extend the Pentagon’s psychedelic research program through 2033, then blocked a…
By Jack Gorsline
Five Phases, Eight Circuits: Chinese Medicine as a Map for Psychedelic Consciousness
Douglas Wingate, a Doctor of Traditional Chinese Medicine and licensed Oregon psilocybin facilitator, maps the…
By Douglas S. Wingate, DTCM, L.Ac.
Psychedelic Policy Briefing: Week of July 20th, 2026
This week in psychedelic policy: Texas moves ahead with state-funded ibogaine trials, Eli Lilly buys…
By Jack Gorsline
What Is Metaprogramming? A Practitioner’s Introduction
Ketamine-assisted therapist Rachel Turetzky explains metaprogramming: John Lilly’s term for consciously rewriting the beliefs that…
By Rachel Turetzky, PhD, CYT, MP-MPr
Psychedelic Policy Briefing: Week of July 13th, 2026
Massachusetts advances a psychedelic therapy pilot program, the FDA finalizes its psychedelic trial guidance and…